News about "Cipla"

Cipla Partners with Stempeutics, Launches Stem Cell Therapy for Knee Osteoarthritis

Cipla has partnered with Stempeutics to launch Ciplostem, a single-dose stem cell therapy for knee osteoarthritis. The treatment uses 25 million expanded Bone Marrow–derived Mesenchymal Stem Cells (BM-MSCs) combined with hyaluronic acid to support joint repair and pain relief.

Cipla | 04/12/2025 | By Dineshwori

Cipla Launches India's First Dedicated Lung Health Diagnostics Centre in Delhi

Cipla has opened the country’s first dedicated lung diagnostics centre in Delhi, equipped to conduct over 60 tests across respiratory function, microbial studies, immune profiling, blood chemistry and imaging.

Cipla | 29/11/2025 | By Dineshwori

Cipla to Acquire Inzpera Healthsciences for INR 110 Crore

Cipla Limited has announced that it will acquire a 100 percent stake in Inzpera Healthsciences Limited for a total consideration of approximately INR 110 crore.

Cipla | 05/11/2025 | By Darshana |  165

Cipla Elevates Achin Gupta as Next Managing Director and Global CEO

Cipla has announced the elevation of Achin Gupta as its next Managing Director and Global Chief Executive Officer, effective April 1, 2026. Currently serving as the company’s Global Chief Operating Officer, Gupta will take over from Umang Vohra, who will step down upon completion of his term on March 31, 2026.

Cipla | 30/10/2025 | By Dineshwori

Kemwell Biopharma's Bengaluru Facility Secures US FDA Clearance for Commercial Manufacturing of Injectable Products

Kemwell Biopharma’s drug-product manufacturing facility in Bengaluru has received clearance from the US Food and Drug Administration (FDA) for the commercial manufacturing and testing of injectable products intended for the US market, following the successful completion of a pre-approval inspection (PAI).

Cipla | 29/10/2025 | By Dineshwori |  128

Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India

Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.

Cipla | 27/10/2025 | By Dineshwori |  220

Bora Biologics Partners with Cipla Subsidiary to Manufacture NYPOZI at San Diego Facility

Bora Biologics has partnered with InvaGen Pharmaceuticals, a wholly owned subsidiary of Cipla Ltd., for the manufacture of NYPOZI at its FDA-registered facility in San Diego, California.

Cipla | 29/09/2025 | By Dineshwori |  170

Cipla launches HUENA, maiden non-antibiotic drug in India for recurring UTIs

With HUENA, Cipla becomes the first in India to offer Methenamine Hippurate, a non-antibiotic therapy for recurrent UTIs, strengthening its fight against AMR.

Cipla | 06/09/2025 | By Dineshwori

Cipla's Bommasandra Facility Gets VAI Classification from USFDA

Cipla has announced that its manufacturing facility in Bommasandra, Bengaluru, has received a Voluntary Action Indicated (VAI) classification from the USFDA following a recent inspection.

Cipla | 06/08/2025 | By Dineshwori |  226

Cipla Appoints BNP and Associates as Secretarial Auditors for Five-Year Term

Cipla Limited has appointed M/s BNP and Associates as its Secretarial Auditors for a five-year term, commencing from the conclusion of the company’s 89th Annual General Meeting (AGM) and continuing until the conclusion of the 94th AGM.

Cipla | 19/07/2025 | By Dineshwori |  157